NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
AMICAR (aminocaproic acid) by KalVista Pharmaceuticals is clinical pharmacology the fibrinolysis-inhibitory effects of amicar appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Approved for anemia. First approved in 1964.
Drug data last refreshed 16h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMICAR (aminocaproic acid) is a fibrinolysis inhibitor that works by blocking plasminogen activators and antiplasmin activity, reducing excessive bleeding. It is indicated for anemia and is administered via injection. The drug has a short half-life of approximately 2 hours with primarily renal elimination.
$0.06MPart D
LOE ApproachingDeclining
Minimal market activity with only $60K in Part D spending and 24 claims signals a niche, mature product with limited team expansion opportunity.
Mechanism of Action
CLINICAL PHARMACOLOGY The fibrinolysis-inhibitory effects of AMICAR appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The…
Indications (1)
Worked on AMICAR at KalVista Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.